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Abstract.
Human vascular endothelial growth factor (VEGF) and its
receptor (VEGFR-2/kinase domain receptor [KDR]) play a
crucial role in angiogenesis, which makes the VEGFR-2
signaling pathway a major target for therapeutic applications.
In this study, a single-chain antibody phage display library was
constructed from spleen cells of mice immunized with
recombinant human soluble extracellular VEGFR-2/KDR
consisting of all seven extracellular domains (sKDR D1–7) to
obtain antibodies that block VEGF binding to VEGFR-2. Two
specific single-chain antibodies (KDR1.3 and KDR2.6) that
recognized human VEGFR-2 were selected; diversity analysis
of the clones was performed by BstNI fingerprinting and
nucleotide sequencing. The single-chain variable fragments
(scFvs) were expressed in soluble form and specificity of
interactions between affinity purified scFvs and VEGFR-2 was
confirmed by ELISA. Binding of the recombinant antibodies for
VEGFR-2 receptors was investigated by surface plasmon
resonance spectroscopy. In vitro cell culture assays showed
that KDR1.3 and KDR2.6 scFvs significantly suppressed the
mitogenic response of human umbilical vein endothelial cells
to recombinant human VEGF165 in a dose-dependent manner,
and reduced VEGF-dependent cell proliferation by 60% and
40%, respectively. In vivo analysis of these recombinant
antibodies in a rat cornea angiogenesis model revealed that
both antibodies suppressed the development of new corneal
vessels (p < 0.05). Overall, in vitro and in vivo results disclose
strong interactions of KDR1.3 and KDR2.6 scFvs with VEGFR-2.
These findings indicate that KDR1.3 and KDR2.6 scFvs are
promising antiangiogenic therapeutic agents.
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1. Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is a physiological phenomenon in embryogene-
sis, wound healing, and the menstruation cycle in the female
reproductive system, but it also occurs in pathological states
such as rheumatoid arthritis, diabetic retinopathy, solid tumors,
hemangioma, psoriasis, and age-related macular degeneration
[1],[2]. As a main component of vessel structure, endothelial
cells play a pivotal role in angiogenic processes. The activation,
proliferation, and migration of these cells result in the forma-
tion of a new blood vessel. Their critical role in angiogenesis
makes endothelial cells primary targets for angiogenesis activa-
tion/inhibition. The “angiogenic switch” is regulated by a tight
balance between proangiogenic and antiangiogenic molecules,
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among which vascular endothelial growth factor (VEGF), an en-
dothelial cell-specific mitogen, is the key modulator [3],[4].
Vascular endothelial growth factor acts through vascular
endothelial growth factor receptor (VEGFR)-1 (flt-1), VEGFR-2
(kinase domain receptor [KDR]), and VEGFR-3 (flt-4) members
of the cell surface receptor-type tyrosine kinase family [5]. An-
other family of receptors, the neuropilins (NRP1 and NRP2), has
also been identified and appears to function as coreceptors to
modulate receptor binding without being active in signaling.
It has been shown that VEGF-induced proliferation and migra-
tion of cells expressing VEGFR-2 are enhanced in the presence
of NRP1 [5–7]. Several studies showed that VEGFR-2 (KDR) is
crucial for VEGF functioning via mediation of endothelial cell
proliferation and chemotaxis [8]. VEGFR-2 (KDR) is expressed at
high levels in endothelial cells and hematopoietic cells [9–11].
KDR has seven extracellular immunoglobulin-like domains that
function in transmission of signals from the environment into
the cytoplasm [12].
Folkman [13] suggested that tumor growth depends on
oxygen and energy resources carried by new capillaries that
develop from nearby blood vessels and asserted that attempts
to block angiogenesis may be an effective approach in inhibit-
ing tumor growth. Later studies demonstrated that antiangio-
genic approaches are promising in cancer treatment [14]; in
particular, antibodies developed against VEGF have been found
to slow tumor growth [15]. An essential role for VEGF in tu-
mor angiogenesis has been demonstrated in animal models,
wherein neutralizing VEGF antibodies and dominant-negative
VEGF receptors block angiogenesis and inhibit disease progres-
sion [14],[16],[17]. Similar studies showed that structures target-
ing VEGF may be useful in cancer treatment. This concept was
demonstrated in a mouse neuroblastoma model using a neutral-
izing antibody [18]. Another study [19] showed that increasing
affinity to neonatal Fc receptor may extend the pharmacoki-
netic half-life of an antibody. Collectively, these studies have
encouraged researchers to develop monoclonal antibodies that
are capable of blocking VEGF and its receptors to prevent tumor
growth, and VEGF antibodies have recently been approved for
clinical use [20].
Monoclonal antibodies are considered the magic bullet
for targeted cancer therapy; however, the large size of an intact
antibody prevents penetration of the tumor mass [21]. To cir-
cumvent this limitation, various studies have demonstrated that
phage display technology can be used to identify new recom-
binant antibody structures [22]. In contrast to whole antibody
structures, recombinant antibodies in the form of single-chain
variable fragments (scFvs) exhibit rapid blood clearance [23],
excellent tumor penetration from the vasculature, and greater
tumor-specific effects in animal models [24].
In this study, we identified scFvs that directly bind VEGFR-
2 and inhibit VEGF-dependent cell proliferation and quantified
their receptor-binding affinities. Phage display method was
used to construct recombinant single-chain antibodies, which
are smaller in molecular size but still retain the VEGF-blocking
property of larger antibodies as described in previous study [25].
Two specific single-chain antibodies (KDR1.3 and KDR2.6 scFvs)
recognizing the extracellular immunoglobulin-like domains 1–7
of VEGFR-2 were selected from a V-gene phage display library
constructed from mice immunized with the commercially avail-
able soluble extracellular domains 1–7 of VEGFR-2 (sKDR D1–7;
AngioBio, CA, USA). KDR1.3 and KDR2.6 scFvs were character-
ized at the DNA and protein levels by ELISA, DNA sequencing,
and surface plasmon resonance (SPR) spectroscopy. Both anti-
KDR scFvs bind to sKDR D1–7, block VEGF binding to sKDR D1–7,
and show potent inhibition of VEGF-induced cell proliferation
in human umbilical vein endothelial cells (HUVECs) by a rat
cornea angiogenesis assay (CAA). Our results demonstrated
that KDR1.3 and KDR2.6 antibodies could inhibit angiogene-
sis via interaction with the VEGFR-2 extracellular domain. Thus,
the identified recombinant antibodies may have potential to be
used as angiogenesis inhibitors.
2. Materials and methods
2.1. Immunization of mice and construction of a scFv
antibody phage display library
For the immunization studies, 7-week-old male Balb/cJ mice
were used (n = 3). The first injection was done by inject-
ing 300 μL of solution containing 150 μL phosphate-buffered
saline (PBS) and 150 μL Freund’s complete adjuvant contain-
ing 10 μg sKDR D1–7 (recombinant human sVEGFR-2 sKDR D1–
7; AngioBio, Del Mar, CA, USA) under the armpit skin of each
mouse. In the third week following the first immunization, the
same amount of mixture was prepared and injected into using
Freund’s incomplete adjuvant. After a 1-month rest period fol-
lowing the second immunization, two mice were injected in the
tail vein with 150 μL PBS containing 10 μg sKDR D1–7. Total RNA
was extracted from spleen with the EZ-RNA Total RNA Isolation
Kit (Biological Industries, Kibbutz Beit Haemek, Israel) 4 days
after the last injection. Complementary DNA (cDNA) was gener-
ated with the hexamer primer-based standard method [26] and
was used as a template for the amplification of immunoglob-
ulin heavy- (VH) and light- (VL) chain variable regions by PCR.
VH variable region amplification was performed in a 50 μL reac-
tion volume containing 5 μL Taq polymerase buffer (10 × ), 3 μL
MgCl2 (25 mM), 1 μL dNTP/10 mM each, 2 μL heavy-chain primer
1 and 2 each (Amersham Pharmacia Biotech, Uppsala, Sweden),
2 μL template cDNA, 1 μL Taq polymerase (1 U/μL) (Fermentas,
Vilnius, Lithuania). VL variable region amplification was per-
formed as VH variable amplification except that 1 μL VL primer
mix was used. The PCR reactions were purified with the Agarose
Gel DNA Extraction Kit (Roche Applied Science, Mannheim,
Germany) and used as a template for the generation of scFv.
The generation of the scFv was performed in two steps.
In the first step, 5 μL Taq polymerase buffer (10 × ), 3 μL
MgCl2 (25 mM), 1 μL dNTP/10 mM each, 3 μL VH PCR product
(100 ng/μL), 3 μL VL PCR product (100 ng/μL), 4 μL linker primer
(Amersham Pharmacia), and 1 μL Taq polymerase (1 U/μL)
(Fermentas) were combined in a 50 μL reaction volume. After
seven cycles of 1 and 4 Min at 94 and 63◦C, respectively, scFv
amplification reaction mix was added (34 μL dH2O, 5 μL Taq
polymerase buffer 10 × , 3 μL MgCl2 25 mM, 1 μL dNTP/10 mM
each, 4 μL RS primer mixture Amersham Pharmacia, 1 μL Taq
polymerase 1 U/μL Fermentas). Then, a second PCR was per-
formed in 25 cycles (94◦C for 1 Min, 55◦C for 2 Min, 72◦C for
2 Min). ScFv PCR products were analyzed by 1.2% agarose gel
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electrophoresis. Assembled ScFv DNA was ligated into pDUCK1
using SfiI/NotI restriction sites and transferred into Echerichia
coli TG1. Transformant colonies were scraped and stored at
–70◦C as library stock.
2.2. Selection of sKDR D1–7-specific recombinant
phages
The library stock was rescued with M13K07 helper phage. The
phage preparation was precipitated in 4% polyethylene glycol
6000/0.5 M NaCl and resuspended in PBS (3.2 mM Na2HPO4 ×
2H2O, 1.4 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4).
Selection of VEGFR-2-binding recombinant antibodies was
performed according to Smith and Scott [27]. In this work, 250 ng
of sKDR D1–7 was incubated overnight in immunotubes (75 ×
12 mm2, Maxisorb; Nunc, Roskilde, Denmark). The tube was
blocked (PBS + 1% bovine serum albumin BSA; Roche) for 1 H
and washed six times with TPBS (PBS + 0.1% v/v Tween-20).
Then, 1011 phage containing the scFv library was added in TPBS.
After 2 H incubation at room temperature, nonbinding phages
were discarded by washing 30 times with TPBS and then 30
times with PBS. The phages were eluted with elution buffer
(0.2 M Glycine pH 2.2, 1 mg/mL BSA; Roche) and the eluate was
neutralized with 75 μL 1 M Tris–HCl (pH 9.1). The eluted phages
were quantified by tritration and then amplified for the second
biopanning step. After the third biopanning step, colonies were
picked for further ELISA experiments.
2.3. Selecting phage-displayed recombinant
antibodies that bind sKDR D1–7 by phage ELISA
Infective phages were obtained from bacteria containing the
scFv genes. Infective phages were used in a phage ELISA. Each
well of a 96-well ELISA plate (BD Falcon, San Diego, CA, USA)
was coated with 500 ng sKDR D1–7 at 4◦C overnight. The next
day, wells were washed three times with TPBS (0.1% Tween
20 in PBS) and blocked for 1 H with TPBS containing 1% BSA.
Wells were washed three times with TPBS and incubated for
2 H with 1011 infective phages. Wells were washed six times
with TPBS and 1:1,000 diluted anti-M13 horseradish peroxi-
dase (HRP)-conjugated antibodies (Pharmacia, Uppsala, Swe-
den) were used as secondary antibodies. The binding signal
was determined with the ELISA reader (Bio-Rad Laboratories,
Richmond, CA, USA) by detecting the absorbance A405 after 1 H
of incubation with ABTS substrate (Pharmacia Biotech, Little
Chalfont Buckinghamshire, England).
2.4. Colony PCR and DNA fingerprinting
The presence of the scFv gene in bacterial colonies was de-
termined by colony PCR. Bacteria were suspended in 15 μL
distilled water. Tubes were incubated at 95◦C for 3 Min and
centrifuged. The upper fluid was used as template for PCR.
Primer 458, 5′-TTTTGTCGTCTTTCCAGACGTT-3′, and primer 459,
5′-TATGACCATGATTACGCCAAG-3′, were used as forward and re-
verse primers. The PCR cycling program was 5 Min at 94◦C then
30 cycles of 1 Min at 94◦C, 2 Min at 55◦C, 2 Min at 72◦C, and
an elongation step of 10 Min at 72◦C. The PCR products were
digested with BstNI enzyme for PCR screening [28].
2.5. DNA sequence analysis of scFv of sKDR
D1–7-binding clones
DNA sequencing was performed with the Beckman Coulter
(Fullerton, CA, USA) GenomeLab Methods Development kit pro-
tocol with primers 459 and 458 for forward and reverse reads.
Sequencing reactions were run in a CEQ 8800 dye termina-
tor cycle sequencing automated sequencing system (Beckman
Coulter). The nucleic acid sequences were analyzed at the
San Diego Supercomputer Center Biology Workbench web site
[29] (http://workbench.sdsc.edu). The variable regions of each
clone were determined by using the ImMunoGeneTics informa-
tion system (IMGT [30]) (http://imgt.cines.fr/).
2.6. ScFv production in bacteria, renaturation of
expressed ScFv, folding and purification
To produce the two recombinant antibodies, the scFv-containing
pDUCK phagemid vector was transferred into E. coli HB2151.
Cells carrying the scFvs were grown overnight at 30◦C in
2 × YT containing ampicillin (100 μg/mL). The preculture
was inoculated into fresh 2 × YT medium containing ampi-
cillin (100 μg/mL) and incubated at 37◦C to D600 (attenu-
ance at 600 nm) of 0.6; induction was performed for 4 H at
30◦C by adding 1 mM (final concentration) isopropyl β-d-1-
thiogalactopyranoside [31]. The cultures were harvested by cen-
trifugation at 2,400g for 10 Min and the supernatants were dis-
carded. Periplasmic extraction of scFv was performed by resus-
pending the pellets in 5.3 mL TES buffer (0.2 M Tris–HCl pH 8.0,
0.5 mM ethylenediaminetetraacetic acid EDTA, 0.5 M sucrose)
and incubating on ice for 5 Min. The cells were incubated on ice
for an additional 20 Min after adding 6 mL of a one-third dilution
of TES buffer. Cells were harvested by centrifugation at 23,700g
for 10 Min at 4◦C. The supernatant was removed and the pellet
was subjected to an inclusion body extraction protocol [32]. The
pellet was dissolved in lysis buffer (50 mM Tris pH 8.0, 200 mM
NaCl, 1 mM EDTA) containing 0.2 mg/mL lysozyme, then soni-
cated six times for 10 Sec after 30 Min incubation on ice and
centrifuged at 17,400g for 15 Min at 4◦C. After the final sonica-
tion step, SDS was added to a final concentration of 1% in the
sonication suspension and incubated at room temperature for
30 Min. The suspension was centrifuged for 30 Min at 17,400g
and 4◦C. The pellet was resuspended in 12 mL lysis buffer and
centrifuged for 20 Min at 17,400g and 4◦C. The pellet was resus-
pended in 50 mM Tris buffer (pH 8.0) containing 6 M urea and
incubated on ice for 45 Min before a final 30 Min centrifugation
(17,400g). Finally, the pellet was resuspended in PBS. Super-
natants were obtained after each centrifugation and analyzed
by SDS-PAGE and western blot.
The final supernatants containing the purified scFvs of
both clones (KDR1.3 and KDR2.6) were dialyzed against refold-
ing buffer (20 mM NaHCO3, 150 mM NaCl, 2 mM EDTA, pH 8.0)
containing l-arginine for two nights at 4◦C and against sonica-
tion buffer (20 mM Tris–HCl pH 8.0, 100 mM NaCl) for two more
nights. The scFvs were extracted from the dialyzed supernatants
on a metal affinity column (BD Bioscience, San Jose, CA, USA).
Eluted samples were dialyzed with PBS and then analyzed by
SDS-PAGE and Western blot. The scFv concentration was
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determined by the bicinchoninic acid method (Pierce Europe,
Oud-Beijerlands, The Netherlands).
2.7. Properties of scFvs binding to sKDR D1–7 ELISA
Each well of an ELISA plate was coated with 500 ng of target
antigen at 4◦C overnight. The next day, the wells were washed
three times with 200 μL TPBS (0.1% Tween-20 in PBS) and then
blocked with 200 μL blocking buffer (PBS + 1% BSA) for 1 H at
room temperature. Wells were then washed with TPBS and 1 μg
anti-KDR recombinant antibodies were added and incubated
at room temperature for 2 H. Wells were washed with TPBS
and anti-Myc tag HRP-conjugated antibody conjugate (Sigma-
Aldrich, Taufkirchen, Germany; 1:5,000) was added and incu-
bated at room temperature for 1 H. A color reaction was acquired
with ABTS substrate solution (Pharmacia Biotech; catalogue
#27-9402-01). After 1 H incubation at room temperature, the
absorbance A405 was detected with an ELISA reader (Bio-Rad).
2.8. SPR spectroscopy
The SPR spectroscopy and SPR slides were obtained from Re-
ichert Instruments (Reichert Technologies, Depew, NY, USA).
The SPR chip surfaces were functionalized overnight with mer-
captoundecanoic acid (Sigma) to form self-assembled monolay-
ers (SAMs) of COOH-terminated thiols. The functionalized SPR
surface was activated by injecting N-hydroxysulfosuccinimide
(NHS)/ethylene dichloride (50 μM NHS and ethanolamine,
Sigma) in a flow cell.
sKDR D1–7 solution was passed across the activated SAM
surface at a constant flow rate (2 μL/Min) at 25◦C. After im-
mobilization of sKDR D1–7 on the surface, loosely bound and
unbound receptors were removed by extensive washing of the
chip surface with buffer solution. To block the amine-coupling
end of SAMs, ethanolamine was passed across the sKDR D1–7
decorated SPR chip surface. Interaction of the recombinant anti-
bodies with sKDR D1–7 was monitored by passing the antibodies
over the chip surface at 1, 2, and 3 μM.
2.9. Culture of HUVECs
Human umbilical vein endothelial cells were isolated and cul-
tured using a modification of the procedure described by Jaffe
et al. [33]. Briefly, untraumatized umbilical cord segments
were cannulated and flushed with Buffer K (10 mM Hepes
pH 7.3, 140 mM NaCl, 4 mM KCl, and 11 mM d-glucose). Cells
were released from the vessel wall by incubating umbilical
veins with 0.05% collagenase/dispase (Roche Molecular Bio-
chemicals, Mannheim, Germany) at 37◦C for 10 Min. The cells
were flushed from the veins with 50 mL Medium 199 (M199)
and after centrifugation (200g, 25◦C, 5 Min) the cell pellet
was washed in M199. Cells were transferred to tissue culture
plates coated with human plasma fibronectin (40 μg/mL) and
maintained in endothelial cell growth medium (ECGM; M199
containing 20% fetal bovine serum FBS, 20 mM Hepes pH
7.4, penicillin 100 U/mL, streptomycin 100 μg/mL, and heparin
5 U/mL Liquemine; Roche) supplemented with crude endothe-
lial growth factor [34]. All cell culture reagents were obtained
from Biochrom (Biochrom KG, Berlin, Germany).
2.10. HUVEC proliferation assay
To test the VEGF blocking activity of the recombinant antibodies,
HUVECs were plated onto 96-well tissue culture plates coated
with 1% gelatin (Sigma) at a density of 5,000 cells/well in ECGM.
After allowing the cells to attach, the medium was replaced with
ECGM containing 2% FBS and cells were cultivated for 16 H. At
this time, recombinant human VEGF165 (rhVEGF165) (5 ng/mL;
NCI, Biological Resources Branch, Rockville, MD, USA) alone or
together with filter-sterilized recombinant antibodies, KDR1.3,
KDR2.6, or VEGF-neutralizing commercial antibody MAB293
(R&D Systems, Minneapolis, MN, USA) were added to ECGM
containing 2% FBS and the cells were incubated for 48 H. In the
last 18 H of incubation, bromodeoxyuridine (BrdU) was added
at a final concentration of 10 μM. At the end of the experiment,
cells were washed and processed for BrdU labeling using the
5-Bromo-2′-deoxy-uridine Labeling and Detection Kit III (Roche
Molecular Biochemicals).
2.11. In vivo CAAs
Inhibitory potentials of antibodies have been investigated with
an in vivo rat CAA. Methodological principles of the experimental
model have been previously described in detail [35]. In brief, hu-
man brain arteriovenous malformation (bAVM) tissue with high
angiogenic potential [36],[37] was obtained, with informed con-
sent, from a patient who underwent a AVM surgical resection
at the Institute of Neurological Sciences, Marmara University
(Istanbul, Turkey). The tissue was implanted into a micropocket
created within the avascular rat cornea. Angiogenesis was stim-
ulated in the avascular corneal matrix with the implantation of
the bAVM tissue. The angiogenic potential of the tissue was
estimated by counting new vessel formation.
Three rats for each group, that is, six corneas for each
antibody (KDR1.3, KDR2.6, and negative control Lig 7 scFv, spe-
cific to hepatitis B virus surface antigen HBsAg) were used.
Antibodies (200 μL, 25 ng/μL) were injected intravenously for
9 days at the same time of day. All groups were followed for 9
days and each cornea was photographed on days 3, 5, 7, and 9
under a microscope (Carl-Zeiss, Göttingen, Germany). The de-
gree of angiogenesis was assessed by a blinded observer who
counted the number of vessels. General linear mode univariate
variation analysis was applied. For the post-hoc comparison,
Tukey’s honestly significant difference and Student–Newman–
Keuls tests were used (SPSS 15.0, SPSS Inc., Chicago, IL, USA).
The results were interpreted and compared as a function of time
by using the cell line charts with error bars indicating one SEM.
3. Results and discussion
Vascular endothelial growth factor expression increases in dif-
ferent types of cancer such as glioblastoma, colorectal cancer,
non-small cell lung cancer, and pancreatic cancer [38]. VEGF and
VEGF receptors are, therefore, priority targets for suppression of
pathologic angiogenesis. It is possible to inhibit VEGF function
by inhibiting different steps in the signaling pathway triggered
by VEGF binding to transmembrane tyrosine kinase receptors on
endothelial cells. Such inhibitory molecules have been devel-
oped against VEGF and VEGF receptors. Today, studies focusing
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Fig. 1. Agarose gel image of variable heavy (VH) chain, light
chain (VL), and the single-chain variable fragment (scFv)
produced from the ligation of variable light and heavy
chains with a linker coding for (Gly4Ser)3.
on suppression of angiogenesis by targeting VEGF and its re-
ceptors have been intensified and many strategies have been
developed to this end. Antibody structures in scFv form were
obtained following immunization of Balb/c mice with the ex-
tracellular domain of KDR fused to human placental alkaline
phosphatase (KDR–AP) [39]. Employing phage display technol-
ogy and using human antibody libraries, candidate antibody
structures for antiangiogenic applications in the form of Fab
and chimeric antibody have been developed [40]. Humanized
monoclonal VEGF antibody bevacizumab [41] and antibody frag-
ment ranibizumab [42] are examples of monoclonal antibody
structures in antiangiogenic clinical applications.
RhuMab VEGF (Bevacizumab), a recombinant human mon-
oclonal VEGF antibody with antiangiogenic and antitumor activ-
ity [43], and the monoclonal human antibody IMC-18F1 against
VEGFR-1 [44] are the most important antiangiogenic agents de-
veloped so far. VEGF-Trap glioma–animal models with VEGFR1
and VEGFR2 structures hybridized to the human immunoglobu-
lin G1 conserved region have been used to demonstrate success-
ful reduction of tumors in the beginning and advanced stages
[45]. Ranibizumab (48.0 kDa) is composed of the Fab (antigen-
binding) section of anti-VEGF monoclonal antibody; smaller than
the monoclonal antibody bevacizumab (148 kDa) from which
it is derived, ranibizumab is able to pass through the internal
membrane after intravitreal application and inhibits all VEGF iso-
forms [46]. Promising results have been obtained in the use of
ranibizumab in age-related macular degeneration [47]. Various
studies have demonstrated that phage display technology can
be effective for the identification of new antiangiogenic recom-
binant antibody structures [48],[49] or tumor-related biomarker
proteins [50].
Fig. 2. Phage ELISA of randomly selected colonies obtained
from the transformation of E. coli TG1 with the ligation
product of anti-KDR scFv.
In this study, instead of using antibodies that are approxi-
mately 150 kDa in size, we used phage display to obtain 33-kDa
recombinant scFv antibodies following selection in a recombi-
nant antibody library developed after immunization of BALB/c J
mice with recombinant sKDR D1–7.
3.1. Library construction and biopanning for
selection of sKDR D1–7-binding scFv
Each mouse was immunized with 15 μg sKDR D1–7. Total RNA
was extracted from spleen cells and cDNAs were generated
by reverse transcription. Using these cDNAs as a template, VH
(340 bp) and VL (325 bp) chain variable regions were PCR am-
plified (Fig. 1). scFv construction was carried out via two-stage
PCR. VH and VL PCR products were assembled into scFv by
PCR using a (Gly4Ser)3 sequence as linker (Fig. 1). Approxi-
mately 750-bp assembled scFvs were digested with NotI and
SfiI and ligated into the phagemid vector pDUCK, then trans-
formed into E. coli TG1 for expression of phage antibody. The
amber codon, positioned between the myc tag and protein III,
enables the construct to make scFv in surface-displaying format
when transformed into a suppressor host (such as E. Coli TGI
cells) and in soluble form when transformed into a nonsupres-
sor host (such as E. Coli HB2151 cells). Enrichment of sKDR
D1–7 binding phages was observed following the third biopan-
ning step, whereas no increase was observed in the binding
phages after the second round. The sKDR D1–7 binding clones
were selected by phage ELISA by coating with 500 ng of sKDR
D1–7 and adding 1011 phages per well (Fig. 2). Eighty clones
were randomly picked after the second round of biopanning and
screened for binding to sKDR D1–7; 11 clones (14%) bound to
sKDR D1–7. The next day, the presence of scFv gene in 45 bacte-
rial colonies was verified by colony PCR as 11 sKDR D1–7 binding
clones and 34 randomly picked sKDR D1–7 nonbinders. The di-
versity of the selected scFv clones was analyzed by BstNI enzyme
fingerprinting.
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Fig. 3. BstNI digestion profile of KDR1.3 and KDR2.6 scFv
clones.
3.2. Sequence analysis
DNA BstNI fingerprinting of 11 sKDR D1–7 binding clones indi-
cated the presence of two different digestion patterns, whereas
34 randomly picked sKDR D1–7 nonbinders yielded four dif-
ferent patterns. Two clones, called KDR1.3 and KDR2.6 scFvs,
were selected for further analysis (Fig. 3). DNA sequences be-
longing to KDR1.3 and KDR2.6 clones were compared with
CLUSTALW-Multiple Sequence Alignment software from the
San Diego Supercomputer Center Biology Workbench web site
(http://workbench.sdsc.edu) and sequence differences con-
firmed the BstNI enzyme digestion results. The DNA sequences
including the complementarity-determining regions of KDR1.3
and KDR2.6 scFvs are given in Figs. 4 and 5. KDR1.3 and KDR2.6
scFvs are 747 and 762 bp long. According to V-QUEST [51] from
the IMGT web site (http://www.imgt.org), the KDR1.3 scFv heavy
chain belongs to the VH3 family, whereas KDR2.6 scFv heavy
chain belongs to the VH1 family, both with light chains belong-
ing to the kappa VL4 family.
3.3. sKDR D1–7 binding of purified scFv
KDR1.3, KDR2.6, and the HBsAg-specific Lig7 scFvs were ex-
pressed using a nonsuppressor host E. coli HB2151 for expres-
sion of soluble scFv in shake flasks. The scFvs were extracted
from cells by a treatment with lysis buffer and sonications. The
soluble scFvs were refolded by dialysis and purified with metal
affinity resin. After purification steps, the amounts of purified
scFvs were 120 ± 35 ng/μL (KDR1.3 ScFv) and 105 ± 20 ng/μL
(KDR2.6 scFv). The ∼33 kDa molecular weight scFvs were de-
termined by SDS-PAGE and western blot analysis (Fig. 6). The
binding ability of both scFvs to sKDR was detected by ELISA
with a mouse anti-human c-myc tag antibody (DakoCytomation)
as well as HRP-labeled polyclonal rabbit anti-mouse antibody
(DakoCytomation) (Fig. 7).
KDR1.3 and KDR2.6 scFvs showed a specific binding signal
of 0.250 and 0.512 at absorbance A405 to sKDR D1–7 but not to
BSA and HBsAg. Lig7 scFv used as control bound specifically
(0.605 at A405) to its antigen (HBsAg) but not to sKDR D1–7.
Solubly expressed KDR1.3 and KDR2.6 scFvs retained their
sKDR D1–7 binding abilities so that they could be used for cell
culture experiments. The sKDR D1–7 binding activities of the
phage display-selected KDR1.3 and KDR2.6 scFvs were also in-
vestigated with SPR spectroscopy. The change in refractive in-
dex is an indication of ligand binding to the receptor molecule
that is immobilized on the chip surface [52]. The binding senso-
grams are demonstrated in Fig. 8.
The binding experiments yielded the real-time binding of
KDR 1.3 and KDR 2.6 to sKDR D1–7 immobilized on SPR chip sur-
face. Another scFv molecule, which specifically binds to HBsAg,
Lig 7, was included in the selectivity test. As shown in Fig. 8,
KDR1.3 and KDR2.6 interacts with sKDR D1–7 but the nonspecific
lig7 does not show significant binding to sKDR D1–7.
3.4. Recombinant antibodies KDR1.3 and KDR2.6
specifically inhibit HUVEC proliferation
To test whether KDR1.3 and KDR2.6 scFvs inhibit VEGF sig-
naling and endothelial cell proliferation, we performed cell
proliferation experiments with recombinant antibody-treated
HUVEC cultures. Inhibition of HUVEC proliferation is an in vitro
assay in which the effect of the antibody on VEGF–VEGFR in-
teraction is measured indirectly through cell proliferation and
is affected by the antibody concentration and affinity. Antibody
293, a commercially available antibody that has been shown
to block endothelial cell proliferation in vitro and VEGF-induced
angiogenesis in vivo, was used as a positive control. As shown in
Fig. 9, KDR1.3 and KDR2.6 scFvs significantly suppressed the mi-
togenic response of HUVEC to rhVEGF165 in a dose-dependent
manner. At 1 μg/mL, antibody 293, KDR1.3 scFv, and KDR2.6
scFv reduced VEGF-dependent proliferation by 84 ± 20.1%,
60 ± 23.7%, and 40 ± 17.4%. Inhibition of proliferation by
both antibodies was significant; however, it was lower than
that of the commercial antibody, which has been reported by
the manufacturer to be 80% with 10 ng/mL rhVEGF. KDR1.3 scFv
yielded consistently higher inhibition at the tested concentra-
tion, but this was statistically insignificant. The inhibition rates
were mean values obtained from four experiments and their
calculated standard deviations were high, resulting in statisti-
cally insignificant differences between the two antibodies. Four
different HUVEC cell proliferation experiments performed with
antibodies obtained from four different preparations, each with
slightly different antibody activities, have contributed to the
variation of cell inhibition effects.
Overall, the inhibition of cell proliferation by KDR1.3 and
KDR2.6 scFvs suggests that the identified recombinant antibod-
ies bind VEGF interfering with receptor interactions on HUVECs.
This inhibition is sufficiently potent to inhibit VEGF signaling
and cell proliferation, which is a downstream event.
The described method has been applied in other studies.
Zhu et al. [53] produced a scFv (p1C11) with 2.1 nM affinity for
KDR by immunizing mice with KDR–AP. They reported 48% inhi-
bition of HUVEC proliferation with 1 μg/mL KDR. Furthermore, a
rat monoclonal antibody developed against Flk1 inhibited G55
cell proliferation by 25% [54]. A monoclonal antibody (YcomB3)
developed against KDR immunoglobulin domain III inhibited
HUVEC proliferation by 50% at 0.5 mg/L and, it was proposed
as a candidate for antiangiogenic applications [55].
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Fig. 4. Protein and DNA sequences of KDR1.3 scFv and the placement of complementarity-determining regions and framework
region (FR) predicted by V-QUEST from the IMGT web site by IMGT [51] (http://www.imgt.org). H, heavy chain; L, light chain.
3.5. In vivo CAAs
Both KDR1.3 and KDR2.6 scFvs successively suppressed the
AVM-induced neovascularization in avascular cornea (p < 0.05).
However, animals in the KDR2.6 group died by day 9 of the assay,
without any observable seizures or symptoms. Representative
cornea images and temporal analysis of vessels for each group
are shown in Figs. 10 and 11.
The in vivo CAA demonstrated that these recombinant
molecules strongly inhibited tissue-induced neovascularization
in rat cornea. Although the number of vessels formed in the Lig
7 control group was ∼18 vessels/cornea at day 7, less than ∼2
vessels/cornea was observed for KDR1.3 and KDR2.6 groups.
However, the death of KDR2.6-injected animals raises concerns
regarding the use of these antibodies in clinical therapy. Avoid-
ing serious toxic effects is critical in oncology because most
regimens contain potent cytotoxic drugs; nevertheless, it has
been difficult to identify biomarkers for toxicity, primarily be-
cause of the low incidence of serious adverse events such as
hemorrhage and perforations. The humanized monoclonal anti-
body bevacizumab is a well-tolerated VEGF inhibitor but carries
the risk of a variety of adverse effects such as hypertension and
pulmonary hemorrhage [56],[57]. Pharmacogenetic variability
has been linked to bevacizumab toxicity [58]. To uncover the
physiopathological causes of the deaths in our experimental
animals, we plan to further perform animal experiments with
KDR2.6 scFv.
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Fig. 5. Protein and DNA sequences of KDR2.6 scFv and the placement of complementarity-determining regions and framework
region (FR) predicted by V-QUEST from the IMGT web site [51] (http://www.imgt.org). H, heavy chain; L, light chain.
4. Conclusion
In this study, we generated and analyzed two single-chain an-
tibodies (KDR1.3 and KDR2.6) specific for the human recom-
binant soluble VEGFR2/KDR domains 1–7, also known as the
KDR receptor. The antibodies bind to the extracellular domain
and block the VEGF–receptor interaction necessary for ligand-
induced proliferation. The molecular characteristics, specificity,
and neutralizing capacities of the these single-chain antibodies
were demonstrated by BstNI fingerprinting; the amino acid se-
quence of the VH and VL domains of the scFv fragments; west-
ern blot analysis of soluble scFvs; ELISA analysis with soluble
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Fig. 6. SDS-PAGE (A) and western blot (B) analysis of metal
affinity column-purified KDR2.6 scFv. Lane 1, molecular
weight marker; lanes 2–9 indicate elution fractions; lane 10,
Lig7 scFv control.
Fig. 7. ELISA of metal-affinity-purified KDR1.3, KDR2.6, and
Lig7 (HBsAg specific) scFvs. Five hundred nanograms of
antigens was immobilized. Binding of scFvs to the antigens
was evaluated by the addition of 1 μg of scFvs, followed by
anti-Myc tag HPR-conjugated antibody. The A405
demonstrates specific binding of KDR1.3 and KDR2.6 scFvs
to sKDR D1–7 and no binding to BSA or HBsAg. No binding
to sKDR D1–7 was visualized for Lig7 scFv but it was
specifically binding to its antigen, HBsAg.
Fig. 8. Comparison of binding signals of selected ligand
molecules, KDR1.3 and KDR2.6, with a nonspecific ligand
molecule, Lig7. The refractive index change corresponds to
the amount of binding.
Fig. 9. Recombinant antibodies KDR1.3 and KDR2.6 inhibit
VEGF-induced HUVEC proliferation in a dose-dependent
manner. HUVECs were grown in M199 containing 2% FBS
without rhVEGF165 (small dotted bars), supplemented with
5 ng/mL rhVEGF165 alone (black bars), 5 ng/mL rhVEGF165
preincubated with 1 μg/mL VEGF-neutralizing antibody
(MAB293) (gray bars), or various concentrations of KDR1.3
scFv (diagonal striped bars), KDR2.6 scFv (light dotted bars),
and Lig 7 scFv (large dotted bars). HUVECs were used at
passage 5. Cell proliferation was quantified in terms of BrdU
incorporation (measured and indicated as OD450). The data
points were obtained in triplicate; representative results
from one of four independent experiments are shown.
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Fig. 10. Representative cornea images from CAA for KDR1.3,
KDR2.6, and Lig7 scFvs. Cornea images were taken under
microscope (Carl-Zeiss) after the treatment of CAA with
KDR1.3, KDR2.6, and Lig7 scFvs at days 3, 5, 7, and 9 for the
calculations of the degree of angiogenesis.
Fig. 11. Temporal analysis of vessels formed in CAA for
KDR1.3, KDR2.6, and Lig 7 scFvs. The degree of angiogenesis
was assessed by a blinded observer who counted the
number of vessels. General linear mode univariate variation
analysis was applied. For the post-hoc comparison, Tukey’s
honestly significant difference and Student–Newman–Keuls
tests were used (SPSS 15.0). The results were interpreted
and compared as a function of time by using the cell line
charts with error bars indicating one SEM.
antigen; and binding of scFv fragments to HUVECs. Results also
showed that KDR1.3 and KDR2.6 scFvs differ from each other,
have specific binding to KDR, and both single-chain antibodies
(clones 1.3 and 2.6) inhibited HUVEC proliferation in vitro up to
40% and 60%, whereas VEGF neutralizing antibody (MAB293)
inhibited between 60% and 80%. In vivo CAA analyses verified
these findings. The identified and characterized new recombi-
nant antibodies, which block VEGF binding to KDR, have po-
tential clinical application in the treatment of cancer and other
diseases involving pathological angiogenesis.
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